Part VI: Summary of the Risk Management Plan

As the safety concerns and their management are identical for all products covered by this RMP, the information in Part VI is presented only once together for all products.

Summary of risk management plan for Emtricitabine+Tenofovir alafenamide Zentiva (emtricitabine/tenofovir alafenamide)
This is a summary of the risk management plan (RMP) for Emtricitabine+Tenofovir alafenamide Zentiva. The RMP details important risks of Emtricitabine+Tenofovir alafenamide Zentiva, how these risks can be minimised, and how more information will be obtained about Emtricitabine+Tenofovir alafenamide Zentiva's risks and uncertainties (missing information).
Emtricitabine+Tenofovir alafenamide Zentiva's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Emtricitabine+Tenofovir alafenamide Zentiva should be used.

Important new concerns or changes to the current ones will be included in updates of Emtricitabine+Tenofovir alafenamide Zentiva's RMP.

I. The medicine and what it is used for

Emtricitabine+Tenofovir alafenamide Zentiva is indicated in combination with other antiretroviral agents for the treatment of adults and adolescents infected with human immunodeficiency virus type 1 (see SmPC for the full indication). It contains emtricitabine and tenofovir alafenamide as the active substances and it is given by oral route.

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of Emtricitabine+Tenofovir alafenamide Zentiva, together with measures to minimise such risks and the proposed studies for learning more about Emtricitabine+Tenofovir alafenamide Zentiva's risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute routine risk minimisation measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed, so that immediate action can be taken as necessary. These measures constitute routine pharmacovigilance activities.

If important information that may affect the safe use of Emtricitabine+Tenofovir alafenamide Zentiva is not yet available, it is listed under 'missing information' below.

II.A List of important risks and missing information

Important risks of Emtricitabine+Tenofovir alafenamide Zentiva are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely taken. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Emtricitabine+Tenofovir alafenamide Zentiva. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine).

Summary of safety concerns	
Important identified risks	• None
Important potential risks	• None
Missing information	• Safety in pregnancy and lactation

II.B Summary of important risks

The safety information in the proposed Product Information is aligned to the reference medicinal product.

II.C Post-authorisation development plan

II.C.1 Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of Emtricitabine+Tenofovir alafenamide Zentiva.

II.C.2 Other studies in post-authorisation development plan

There are no studies required for Emtricitabine+Tenofovir alafenamide Zentiva.